Enzo von Quednow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Enzo von Quednow has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Paweł Łajczak
Medical University of Silesia
3 shared publications - Fabio Victor Vieira Rocha
Department of Neurosurgery, Federal University of Espírito Santo, (UFES), Vitoria, Brazil
2 shared publications - Guilherme Linha Secco
State University of Ponta Grossa, Ponta Grossa, Brazil
2 shared publications - Oguz Kagan Sahin
Geneuro - International Research Group in Neuroscience, Vitoria, Brazil
2 shared publications - Walter Fagundes
Department of Neurosurgery, Federal University of Espirito Santo, Vitoria, Brazil
2 shared publications - Yasmin Picanço Silva
University of Debrecen, Debrecen, Hungary
2 shared publications
Latest Publications
- 11 March 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (7) , 1702-1709
Recurrent IRF2BPL c.2152del Variant in NEDAMSS : A Case Report and Comparative Analysis
We describe a male child with a de novo IRF2BPL c.2152del (p.Cys718Alafs*49) frameshift variant presenting with early‐onset NEDAMSS and West Syndrome, and compare this phenotype with two previously reported cases carrying the same variant. This is the third report of this specific variant and the first to include a comparative phenotypic analysis, highlighting a potentially consistent and severe clinical pattern. The patient was identified through clinical evaluation and exome sequencing (ES) after presenting with early developmental regression and drug‐resistant epilepsy. A literature search identified two additional cases with the same variant and a comparative analysis was conducted. The patient showed neonatal axial hypotonia, early neurodevelopmental regression and epilepsy evolving into West syndrome. Brain MRI revealed corpus callosum thinning and hippocampal malrotation. EEG evolved from burst‐attenuation to hypsarrhythmia. ES identified a de novo c.2152del IRF2BPL variant. In comparison, all three cases shared profound hypotonia, severe neurodevelopmental impairment, and early‐onset epileptic encephalopathy. These findings support the pathogenicity of the c.2152del variant and suggest its potential association with a severe early‐onset NEDAMSS phenotype. Generalizability remains limited by the small number of cases, and confirmation requires further clinical and functional evidence.
- 11 March 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (7) , 1702-1709
Recurrent IRF2BPL c.2152del Variant in NEDAMSS : A Case Report and Comparative Analysis
We describe a male child with a de novo IRF2BPL c.2152del (p.Cys718Alafs*49) frameshift variant presenting with early‐onset NEDAMSS and West Syndrome, and compare this phenotype with two previously reported cases carrying the same variant. This is the third report of this specific variant and the first to include a comparative phenotypic analysis, highlighting a potentially consistent and severe clinical pattern. The patient was identified through clinical evaluation and exome sequencing (ES) after presenting with early developmental regression and drug‐resistant epilepsy. A literature search identified two additional cases with the same variant and a comparative analysis was conducted. The patient showed neonatal axial hypotonia, early neurodevelopmental regression and epilepsy evolving into West syndrome. Brain MRI revealed corpus callosum thinning and hippocampal malrotation. EEG evolved from burst‐attenuation to hypsarrhythmia. ES identified a de novo c.2152del IRF2BPL variant. In comparison, all three cases shared profound hypotonia, severe neurodevelopmental impairment, and early‐onset epileptic encephalopathy. These findings support the pathogenicity of the c.2152del variant and suggest its potential association with a severe early‐onset NEDAMSS phenotype. Generalizability remains limited by the small number of cases, and confirmation requires further clinical and functional evidence.
- 28 October 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-12
Non-invasive versus invasive techniques for predicting idiopathic normal-pressure hydrocephalus in shunt-responsive patients
The diagnosis of normal-pressure hydrocephalus (NPH) can be challenging, particularly distinguishing between shunt-responsive and non-responsive patients. Overlapping clinical symptoms with aging and neurodegenerative diseases such as Alzheimer’s and Parkinson’s may hinder its diagnosis. Thus, more effective diagnostic tools are necessary To compare non-invasive techniques, such as electroencephalography (EEG), transcranial Doppler (TCD), intracranial compliance (ICC) measurement, and optical coherence tomography (OCT), with invasive procedures, such as lumbar puncture (LP) and infusion tests (IT), in the prediction of shunt responsiveness in patients with idiopathic normal pressure hydrocephalus (iNPH). A systematic search of PubMed, Embase, and the Cochrane Library from 2013 to March 2023 identified studies that evaluated both invasive procedures (e.g., LP, IT) and non-invasive methods (e.g., EEG, TCD, ICC, OCT). Ten studies including 401 elderly patients with iNPH were analyzed. EEG biomarkers consistently differentiated responders, with three reproducible patterns: decreased frontal theta/delta power, increased temporal gamma power (sensitivity 83%, specificity 88%), and alpha rhythm normalization. Non-responders showed persistent slow delta waves in the frontal region and beta asymmetry. TCD revealed a 20% increase in the middle cerebral artery flow velocity after cerebrospinal fluid withdrawal in responders, correlating with motor improvement. OCT showed thinner ganglion cell layers in responders, while ICC suggested changes in brain compliance. Combined, these biomarkers may contribute to a more comprehensive predictive framework. While promising, non-invasive iNPH biomarkers remain insufficiently validated. No non-invasive test currently matches the reliability of invasive methods, which continue to represent the gold standard. Long-term data are lacking, and these tools should be considered as complementary rather than replacements for standard diagnostics.
- 28 October 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-12
Non-invasive versus invasive techniques for predicting idiopathic normal-pressure hydrocephalus in shunt-responsive patients
The diagnosis of normal-pressure hydrocephalus (NPH) can be challenging, particularly distinguishing between shunt-responsive and non-responsive patients. Overlapping clinical symptoms with aging and neurodegenerative diseases such as Alzheimer’s and Parkinson’s may hinder its diagnosis. Thus, more effective diagnostic tools are necessary To compare non-invasive techniques, such as electroencephalography (EEG), transcranial Doppler (TCD), intracranial compliance (ICC) measurement, and optical coherence tomography (OCT), with invasive procedures, such as lumbar puncture (LP) and infusion tests (IT), in the prediction of shunt responsiveness in patients with idiopathic normal pressure hydrocephalus (iNPH). A systematic search of PubMed, Embase, and the Cochrane Library from 2013 to March 2023 identified studies that evaluated both invasive procedures (e.g., LP, IT) and non-invasive methods (e.g., EEG, TCD, ICC, OCT). Ten studies including 401 elderly patients with iNPH were analyzed. EEG biomarkers consistently differentiated responders, with three reproducible patterns: decreased frontal theta/delta power, increased temporal gamma power (sensitivity 83%, specificity 88%), and alpha rhythm normalization. Non-responders showed persistent slow delta waves in the frontal region and beta asymmetry. TCD revealed a 20% increase in the middle cerebral artery flow velocity after cerebrospinal fluid withdrawal in responders, correlating with motor improvement. OCT showed thinner ganglion cell layers in responders, while ICC suggested changes in brain compliance. Combined, these biomarkers may contribute to a more comprehensive predictive framework. While promising, non-invasive iNPH biomarkers remain insufficiently validated. No non-invasive test currently matches the reliability of invasive methods, which continue to represent the gold standard. Long-term data are lacking, and these tools should be considered as complementary rather than replacements for standard diagnostics.
- Open Access
- 3 October 2025
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 46 (6) , 104727
Machine learning model for predicting hearing preservation after vestibular schwannoma surgery: A meta-analysis
- 3 October 2025
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 46 (6) , 104727
Open AccessMachine learning model for predicting hearing preservation after vestibular schwannoma surgery: A meta-analysis
- 17 September 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2111005
Diagnostic accuracy of the Gold Coast Criteria for amyotrophic lateral sclerosis: a systematic review and meta-analysis
- 17 September 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 179, 2111005
Diagnostic accuracy of the Gold Coast Criteria for amyotrophic lateral sclerosis: a systematic review and meta-analysis
- Open Access
- 4 August 2025
- Published by Wolters Kluwer Health in Spine
- Vol. 50 (21) , E438-E448
Optimal Tranexamic Acid Dosing for Adolescent Idiopathic Scoliosis Surgery
Study design.: Systematic review and network meta-analysis (NMA). Objective.: This NMA evaluates the clinical efficacy and safety of various doses of Tranexamic acid (TXA) for adolescent idiopathic scoliosis (AIS) instrumentation. Summary of background data.: TXA is an antifibrinolytic agent widely used in spine surgery. However, the optimal TXA dose remains unclear, especially for younger patients. Methods.: We performed a systematic search across PubMed, Scopus, Web of Science, and the Cochrane Library up to March 2025. We included studies that compared different TXA doses or patients without TXA in AIS surgery. We evaluated five TXA doses: TXA 0 (control without TXA); TXA 1 (10 mg/kg bolus + 1 mg/kg/hr infusion); TXA 2 (15–20 mg/kg bolus + 1–10 mg/kg/hr infusion); TXA 3 (30–50 mg/kg bolus of TXA + 5–10 mg/kg/hr infusion); and TXA 4 (100 mg/kg bolus of TXA + 10 mg/kg/hr infusion). This meta-analysis compared bleeding volume, surgical time, transfusion rates, length of hospital stay, and complications. Random-effects frequentist NMA was employed. Treatments were ranked with P-scores. Results.: A total of 1,523 patients, mainly aged 13 to 18 years from 16 studies were included in this analysis (eight retrospective studies). TXA 4 outperformed other doses in reducing intraoperative bleeding, operation time, and cell saver volume. TXA 3 also showed significant benefits but was less effective than TXA 4. There was no difference in complication rates, although these data were not uniformly reported in the studies. No evidence of publication bias was found. Quality concerns were observed. Conclusion.: The tranexamic acid dose of 100 mg/kg bolus + 10 mg/kg/hr infusion (TXA 4) was the most effective in bleeding control during AIS instrumentation in teenagers. While these results are promising, more randomized trials are needed to directly compare various TXA doses.
- 4 August 2025
- Published by Wolters Kluwer Health in Spine
- Vol. 50 (21) , E438-E448
Open AccessOptimal Tranexamic Acid Dosing for Adolescent Idiopathic Scoliosis Surgery
Study design.: Systematic review and network meta-analysis (NMA). Objective.: This NMA evaluates the clinical efficacy and safety of various doses of Tranexamic acid (TXA) for adolescent idiopathic scoliosis (AIS) instrumentation. Summary of background data.: TXA is an antifibrinolytic agent widely used in spine surgery. However, the optimal TXA dose remains unclear, especially for younger patients. Methods.: We performed a systematic search across PubMed, Scopus, Web of Science, and the Cochrane Library up to March 2025. We included studies that compared different TXA doses or patients without TXA in AIS surgery. We evaluated five TXA doses: TXA 0 (control without TXA); TXA 1 (10 mg/kg bolus + 1 mg/kg/hr infusion); TXA 2 (15–20 mg/kg bolus + 1–10 mg/kg/hr infusion); TXA 3 (30–50 mg/kg bolus of TXA + 5–10 mg/kg/hr infusion); and TXA 4 (100 mg/kg bolus of TXA + 10 mg/kg/hr infusion). This meta-analysis compared bleeding volume, surgical time, transfusion rates, length of hospital stay, and complications. Random-effects frequentist NMA was employed. Treatments were ranked with P-scores. Results.: A total of 1,523 patients, mainly aged 13 to 18 years from 16 studies were included in this analysis (eight retrospective studies). TXA 4 outperformed other doses in reducing intraoperative bleeding, operation time, and cell saver volume. TXA 3 also showed significant benefits but was less effective than TXA 4. There was no difference in complication rates, although these data were not uniformly reported in the studies. No evidence of publication bias was found. Quality concerns were observed. Conclusion.: The tranexamic acid dose of 100 mg/kg bolus + 10 mg/kg/hr infusion (TXA 4) was the most effective in bleeding control during AIS instrumentation in teenagers. While these results are promising, more randomized trials are needed to directly compare various TXA doses.